Inventor
SINGH SHWETA
US21 patents
⚠️ This page may combine multiple inventors who share the name “SINGH SHWETA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CYTOMX THERAPEUTICS INC
7 patentsUS10745481B2Aug 18, 2020
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC22 citations94
US10233244B2Mar 19, 2019
Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC26 citations93
US10179817B2Jan 15, 2019
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC36 citations93
US9517276B2Dec 13, 2016
Compositions and methods for conjugating activatable antibodies
CYTOMX THERAPEUTICS INC24 citations92
US11753466B2Sep 12, 2023
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC7 citations85
US11267896B2Mar 8, 2022
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC10 citations85
US11992528B2May 28, 2024
Compositions and methods for conjugating activatable antibodies
CYTOMX THERAPEUTICS INC0 citations60
TAKEDA PHARMACEUTICALS CO
7 patentsUS10494444B2Dec 3, 2019
Anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO8 citations92
US10336833B2Jul 2, 2019
Conjugated anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO9 citations92
US9676869B2Jun 13, 2017
Conjugated anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO12 citations92
US9790285B2Oct 17, 2017
Anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO7 citations83
US12312411B2May 27, 2025
Anti-CD38 binding domains
TAKEDA PHARMACEUTICALS CO0 citations62
US12209138B2Jan 28, 2025
Anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO0 citations62
US11434304B2Sep 6, 2022
Anti-CD38 antibodies
TAKEDA PHARMACEUTICALS CO0 citations62